前次募集资金使用情况报告（二次修订稿） 证券代码：688166 证券简称：博瑞医药 公告编号：2025-059 博瑞生物医药（苏州）股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会颁布的《上市公司证券发行注册管理办法》及 《监管规则适用指引——发行类第 7 号》的规定，博瑞生物医药（苏州）股份有 限公司（以下简称"博瑞医药"、"公司"）编制了截至 2025 年 6 月 30 日的前 次募集资金使用情况报告（二次修订稿）（以下简称"前次募集资金使用情况报 告"）。 一、前次募集资金情况 （一）前次募集资金金额、资金到位时间 ①2019 年首次公开发行股票募集资金情况 经中国证券监督管理委员会下发的《关于同意博瑞生物医药（苏州）股份有 限公司首次公开发行股票注册的批复》（证监许可〔2019〕1883 号），公司首 次向社会公众公开发行人民币普通股（A 股）41,000,000 股，每股面值人民币 1 元，每股发行价格为人民币 12.71 元，募集资金总额为人民币 521,110,000. ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-058 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"、"本公司" 或"公司"）董事会根据中国证券监督管理委员会《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》的规定，编制了《2025 年半年度募集资金存放 与使用情况的专项报告》。 一、募集资金基本情况 （一）2019 年首次公开发行股票募集资金情况 1、实际募集资金金额、资金到账时间 根据中国证券监督管理委员会出具的《关于同意博瑞生物医药（苏州）股份 有限公司首次公开发行股票注册的批复》（证监许可〔2019〕1883 号），公司 首次向社会公众公开发行人民币普通股（A 股）41,000,000 股，每股面值人民币 1 元，每股发行价格为人民币 12.71 元，募集资金总额为人民币 521,110,000.00 元，扣 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-060 博瑞生物医药（苏州）股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会计政策变更系根据近期发布的企业会计准则及其相关规定进行， 本次变更不会对博瑞生物医药（苏州）股份有限公司（以下简称"公司"）的财 务状况、经营成果和现金流量产生重大影响，亦不存在损害公司及股东利益的情 况。 一、会计政策变更概述 2025 年 7 月 18 日，中国证券监督管理委员会发布《监管规则适用指引—— 会计类第 5 号》（以下简称"会计类 5 号"），对财政部发布的《企业会计准则第 18 号——所得税》等关于递延所得税初始确认豁免相关规定给予进一步的处理意 见。会计类 5 号指出，监管实践发现，部分发行可转换债券的公司对于是否应确 认发行可转换债券相关递延所得税负债，存在理解上的偏差和分歧。会计类 5 号 就上述问题明确了处理意见，公司需适用该规范性文件。 公司自会计类 5 号发布之日起执行上述规定，并根据上述规定，对 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-056 博瑞生物医药（苏州）股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）第四届监事会第 九次会议于 2025 年 8 月 28 日以现场会议加通讯表决方式在 C27 栋会议室召开。 本次会议通知以及相关材料已于 2025 年 8 月 15 日以邮件方式送达公司全体监 事。 本次会议应出席监事 5 名，实到 5 名，会议由何幸先生召集。本次会议的召 集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规 定。 二、监事会会议审议情况 （一）审议通过《2025 年半年度报告及摘要》 监事会认为：公司 2025 年半年度报告的编制和审议程序符合法律法规和《公 司章程》的规定。报告内容真实、准确、完整的反映了公司 2025 年上半年经营 的实际情况，未发现参与 2025 年半年度报告编制和审议人员有违反保密规定的 行为。监事会保 ...

博瑞生物医药（苏州）股份有限公司 二、独立董事专门会议审议情况 1. 审议通过《关于修订公司前次募集资金使用情况专项报告的议案》 经审议，独立董事一致认为《博瑞生物医药（苏州）股份有限公司前次募集 资金使用情况报告（二次修订稿）》内容真实、准确、完整，不存在虚假记载、 误导性陈述和重大遗漏，公司前次募集资金具体使用情况与公司已披露情况一致， 不存在变相改变募集资金用途和损害股东利益的情况，不存在违规使用募集资金 的情形，一致同意《博瑞生物医药（苏州）股份有限公司前次募集资金使用情况 报告（二次修订稿）》，并同意将该议案提交公司董事会审议。 表决结果：3 票同意；0 票反对；0 票弃权。 博瑞生物医药（苏州）股份有限公司 第四届董事会独立董事第五次专门会议决议 一、独立董事专门会议召开情况 博瑞生物医药（苏州）股份有限公司（下称"公司"）第四届董事会独立董 事第五次专门会议于 2025 年 8 月 28 日以通讯表决方式召开。本次会议应出席独 立董事 3 名，实到 3 名，会议由独立董事许冬冬先生主持。本次会议的召集、召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 独立董事：程增江、许 ...

二、董事会会议审议情况 （一）审议通过《2025 年半年度报告及摘要》 证券代码：688166 证券简称：博瑞医药 公告编号：2025-055 博瑞生物医药（苏州）股份有限公司 第四届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）第四届董事会第 十次会议于 2025 年 8 月 28 日以现场会议加通讯表决方式在 C27 栋会议室召开。 本次会议通知以及相关材料已于2025年8月15日以邮件方式送达公司全体董事。 本次会议应出席董事 9 名，实到 9 名，会议由袁建栋先生召集和主持。本次 会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定。 具体内容详见公司同日披露于上海证券交易所的公告。 表决结果：9 票同意；0 票反对；0 票弃权。 本议案已经公司第四届董事会审计委员会第四次会议审议通过，同意将该议 案提交公司董事会审议。 （二）审议通过《2025 年半年度募集资金存放与使用情况的专项 ...

博瑞生物医药（苏州）股份有限公司 前次募集资金使用情况鉴证报告 前次募集资金使用情况鉴证报告 苏公W[2025]E1395号 博瑞生物医药（苏州）股份有限公司全体股东： 我们接受委托，对后附的博瑞生物医药（苏州）股份有限公司（以下简 称博瑞医药）截至2025年6月30日止的前次募集资金使用情况报告进行了鉴 证。 一、董事会的责任 2025 年 6 月 30 日 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国. 江苏. 无锡 Wuxi . Jiangsu . China 总机：86 (510)68798988 Tel： 86 (510)68798988 传真：86 (510)68567788 Fax： 86 (510)68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 按照中国证券监督管理委员会《监管规则适用指引——发行类第7号》 的规定编制前次募集资金使用情况报告，并保证其内容真实、准确、完整， 不存在虚假记录、误导性陈述或重大遗漏是博瑞医药董事会的责任。 二 ...

Financial Performance - The company's operating revenue for the first half of 2025 was approximately ¥537.44 million, a decrease of 18.28% compared to the same period last year[17]. - The total profit for the period was a loss of approximately ¥5.02 million, representing a decline of 105.32% year-on-year[17]. - The net profit attributable to shareholders was approximately ¥17.17 million, down 83.85% from the previous year[17]. - The net cash flow from operating activities was approximately ¥113.61 million, a decrease of 24.87% compared to the same period last year[17]. - Basic earnings per share decreased by 84.00% to CNY 0.04 compared to the same period last year[18]. - The main business gross margin was 49.70%, indicating a high profitability level[93]. - The company reported a total loss of CNY 2,404,940.18 from hedging activities during the reporting period[109]. - The company reported a net loss of approximately ¥40.55 million for the period[192]. Research and Development - Research and development expenses accounted for 64.83% of operating revenue, an increase of 43.12 percentage points compared to the same period last year[19]. - R&D investment reached CNY 348.44 million, a year-over-year increase of 144.07%, accounting for 64.83% of total revenue[41]. - The company focused on developing innovative drugs in the metabolic disease field, with 91.22% of R&D investment directed towards innovative drugs and inhalation formulations, showing a year-over-year increase of 319.72%[41]. - The innovative drug BGM0504 injection for type 2 diabetes and weight loss has completed patient enrollment for its domestic Phase III clinical trial and is progressing as planned[42]. - The company is actively investing in innovative technology firms to enhance its future drug pipeline[30]. - The company is developing a long-acting amylin analog, BGM1812 injection, with a total investment of CNY 10,000 million, currently in preclinical research[76]. - The company has submitted 24 domestic patent applications and received 9 domestic patent grants during the reporting period, with a total of 549 patent applications filed to date[46]. Market Strategy - The company plans to increase market share through participation in national centralized procurement, with a focus on improving hospital coverage for its products[27]. - The company has developed a multi-channel marketing strategy, combining direct supply, agency sales, and self-promotion to enhance its market presence[27]. - The company is focusing on GLP-1 class drugs and exploring multi-target therapies to expand clinical applications[32]. - The company aims to explore new delivery methods and expand indications for GLP-1 class drugs, focusing on oral formulations and long-acting release formulations to enhance patient compliance[61]. Risk Management - The company has outlined various risks in its report, which are detailed in the management discussion and analysis section[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a commitment to investors[6]. - The company faces significant risks in the development of generic drugs due to high investment and long cycles[82]. - The company is exposed to innovation drug development risks, including potential clinical trial failures and regulatory approval challenges[83]. - The company has established internal control measures to manage risks associated with foreign exchange derivatives, including liquidity and operational risks[109]. Investments and Assets - The company has raised CNY 465 million through convertible bonds for the construction of a production base and R&D center, with 85% of the project completed[47]. - The company’s total assets rose by 4.41% to approximately ¥5.38 billion compared to the end of the previous year[17]. - The company’s long-term equity investments increased by 254.92% to 138,570.97 million RMB, mainly due to additional investments in Shenzhen Aoli Biotechnology Co., Ltd.[102]. - The company has a total of 386.11 million RMB in liquid assets, with a net profit of -14.37 million RMB reported[111]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 9,568[151]. - The largest shareholder, Yuan Jiandong, holds 113,535,123 shares, representing 26.86% of the total shares[153]. - The company has not reported any changes in the use of raised funds or any violations regarding the use of raised funds[148]. - The company has commitments from major shareholders and related parties to avoid competition, effective since March 18, 2019, and these commitments are long-term and strictly enforced[121]. Compliance and Legal Matters - The company received a notice from the Jiangsu Provincial High People's Court regarding a retrial application related to a civil judgment, indicating ongoing legal proceedings[127]. - The company was issued a warning letter by the Jiangsu Securities Regulatory Bureau due to non-compliance with information disclosure obligations, specifically regarding the management of idle raised funds amounting to RMB 380 million[128]. - The company has committed to enhancing compliance with relevant laws and regulations following the warning letter, focusing on accurate and complete information disclosure[129]. - There are no significant litigation or arbitration matters reported for the current period, indicating a stable legal standing[126].

民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构 | 民生证券股份有限公司 | 上市公司简称 | 博瑞医药 | | --- | --- | --- | --- | | 保荐代表人 | 黄丹青、邵航 | 上市公司代码 | 688166 | 经中国证券监督管理委员会《关于同意博瑞生物医药（苏州）股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕1883 号）核准，并经上海证 券交易所同意，博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或 "公司"）向社会公众公开发行人民币普通股（A 股）股票 41,000,000 股，每股 发行价格为人民币 12.71 元，募集资金总额 521,110,000.00 元，扣除承销及保荐 费用、会计师费用、律师费用、信息披露费用及其他发行手续费共计人民币 81,125,361.23 元后，募集资金净额为人民币 439,984,638.77 元。上述募集资金已 于 2019 年 10 月 31 日全部到位，且经公证天业会计师事务所（特殊普通合伙） 审验并出具了苏公 W[2019]B079 号《验资报告》 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.45% on August 28, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Top Performers - Duorui Pharmaceutical (301075) saw a closing price of 44.40, with a rise of 7.87% and a trading volume of 59,400 shares, totaling a transaction value of 259 million [1] - Guangshengtang (300436) closed at 131.39, up 5.49%, with a trading volume of 172,000 shares and a transaction value of 2.192 billion [1] - Xingqi Eye Medicine (300573) closed at 68.70, increasing by 3.71%, with a trading volume of 318,800 shares and a transaction value of 2.239 billion [1] Underperformers - Nanjing New Pharmaceutical (681899) closed at 15.41, down 9.25%, with a trading volume of 455,800 shares and a transaction value of 701 million [2] - Meinuohua (603538) closed at 26.04, down 8.18%, with a trading volume of 387,900 shares and a transaction value of 1.017 billion [2] - Borui Pharmaceutical (688166) closed at 98.04, down 6.63%, with a trading volume of 225,300 shares and a transaction value of 2.201 billion [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 3.702 billion from institutional investors, while retail investors contributed a net inflow of 3.086 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Huadong Pharmaceutical (000963) had a net inflow of 89.0375 million from institutional investors, while retail investors saw a net outflow of 84.9691 million [3] - Guangshengtang (300436) experienced a net inflow of 52.2637 million from institutional investors, with retail investors also seeing a net outflow of 25.6366 million [3] - Nanjing New Pharmaceutical (688189) had a net inflow of 17.9937 million from institutional investors, while retail investors faced a net outflow of 41.5515 million [3]